Cargando…

Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease in which many processes are detected including (neuro)inflammation. Many drugs have been tested for ALS in clinical trials but most have failed to reach their primary endpoints. The development and inclusion of different...

Descripción completa

Detalles Bibliográficos
Autores principales: Staats, Kim A., Borchelt, David R., Tansey, Malú Gámez, Wymer, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785449/
https://www.ncbi.nlm.nih.gov/pubmed/35073950
http://dx.doi.org/10.1186/s13024-022-00515-1
_version_ 1784638966781181952
author Staats, Kim A.
Borchelt, David R.
Tansey, Malú Gámez
Wymer, James
author_facet Staats, Kim A.
Borchelt, David R.
Tansey, Malú Gámez
Wymer, James
author_sort Staats, Kim A.
collection PubMed
description Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease in which many processes are detected including (neuro)inflammation. Many drugs have been tested for ALS in clinical trials but most have failed to reach their primary endpoints. The development and inclusion of different types of biomarkers in diagnosis and clinical trials can assist in determining target engagement of a drug, in distinguishing between ALS and other diseases, and in predicting disease progression rate, drug responsiveness, or an adverse event. Ideally, among other characteristics, a biomarker in ALS correlates highly with a disease process in the central nervous system or with disease progression and is conveniently obtained in a peripheral tissue. Here, we describe the state of biomarkers of inflammation in ALS by focusing on peripherally detectable and cellular responses from blood cells, and provide new (combinatorial) directions for exploration that are now feasible due to technological advancements.
format Online
Article
Text
id pubmed-8785449
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87854492022-01-24 Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis Staats, Kim A. Borchelt, David R. Tansey, Malú Gámez Wymer, James Mol Neurodegener Review Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease in which many processes are detected including (neuro)inflammation. Many drugs have been tested for ALS in clinical trials but most have failed to reach their primary endpoints. The development and inclusion of different types of biomarkers in diagnosis and clinical trials can assist in determining target engagement of a drug, in distinguishing between ALS and other diseases, and in predicting disease progression rate, drug responsiveness, or an adverse event. Ideally, among other characteristics, a biomarker in ALS correlates highly with a disease process in the central nervous system or with disease progression and is conveniently obtained in a peripheral tissue. Here, we describe the state of biomarkers of inflammation in ALS by focusing on peripherally detectable and cellular responses from blood cells, and provide new (combinatorial) directions for exploration that are now feasible due to technological advancements. BioMed Central 2022-01-24 /pmc/articles/PMC8785449/ /pubmed/35073950 http://dx.doi.org/10.1186/s13024-022-00515-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Staats, Kim A.
Borchelt, David R.
Tansey, Malú Gámez
Wymer, James
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis
title Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis
title_full Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis
title_fullStr Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis
title_full_unstemmed Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis
title_short Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis
title_sort blood-based biomarkers of inflammation in amyotrophic lateral sclerosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785449/
https://www.ncbi.nlm.nih.gov/pubmed/35073950
http://dx.doi.org/10.1186/s13024-022-00515-1
work_keys_str_mv AT staatskima bloodbasedbiomarkersofinflammationinamyotrophiclateralsclerosis
AT borcheltdavidr bloodbasedbiomarkersofinflammationinamyotrophiclateralsclerosis
AT tanseymalugamez bloodbasedbiomarkersofinflammationinamyotrophiclateralsclerosis
AT wymerjames bloodbasedbiomarkersofinflammationinamyotrophiclateralsclerosis